VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity BioworksConference Call to be Held Today at 1:30 PM PT / 4:30 PM ETSAN ANTONIO , May 14, 2026...

Valion Bio Appoints Melinda Lackey as General Counsel

Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership TeamSAN ANTONIO, May 4, 2026 /PRNewswire/ — Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage...